In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum.

PubWeight™: 0.86‹?›

🔗 View Article (PMC 3088194)

Published in Antimicrob Agents Chemother on February 28, 2011

Authors

Fabiana Morandi Jordão1, Alexandre Yukio Saito, Danilo Ciccone Miguel, Valnice de Jesus Peres, Emília Akemi Kimura, Alejandro Miguel Katzin

Author Affiliations

1: Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, Av. Professor Lineu Prestes 1374, CEP 05508-000, São Paulo, SP, Brazil.

Articles cited by this

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65

Human malaria parasites in continuous culture. Science (1976) 59.70

Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77

Regulation of the mevalonate pathway. Nature (1990) 18.25

Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49

Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu Rev Biochem (1992) 4.20

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res (1998) 3.65

Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem (2001) 2.26

Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res (2000) 1.70

Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. J Biol Chem (2002) 1.52

Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol (1998) 1.39

Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs. J Biol Chem (1999) 1.39

Screening Tanzanian medicinal plants for antimalarial activity. Acta Trop (1994) 1.38

Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem (2008) 1.37

Transporters as mediators of drug resistance in Plasmodium falciparum. Int J Parasitol (2010) 1.36

Bisphosphonates in cancer therapy. Cancer Lett (2007) 1.36

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum (2001) 1.31

Protein prenyl transferase activities of Plasmodium falciparum. Mol Biochem Parasitol (1998) 1.30

Chain-length determination mechanism of isoprenyl diphosphate synthases and implications for molecular evolution. Trends Biochem Sci (1999) 1.30

Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs. Curr Opin Investig Drugs (2004) 1.25

Active isoprenoid pathway in the intra-erythrocytic stages of Plasmodium falciparum: presence of dolichols of 11 and 12 isoprene units. Biochem J (1999) 1.22

Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21

The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem (2007) 1.16

Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum. Antimicrob Agents Chemother (2004) 1.15

In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 1.14

Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem (2005) 1.13

Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis (2002) 1.10

The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth. Mol Biochem Parasitol (1998) 1.09

N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum. J Biol Chem (1996) 1.08

In vivo time course of synthesis and processing of major schizont membrane polypeptides in Plasmodium falciparum. Mol Biochem Parasitol (1986) 1.07

Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth. Antimicrob Agents Chemother (2010) 1.07

Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites. Curr Drug Targets Infect Disord (2001) 1.04

Isoprenoid biosynthesis of the apicoplast as drug target. Curr Drug Targets (2007) 1.03

Limonene arrests parasite development and inhibits isoprenylation of proteins in Plasmodium falciparum. Antimicrob Agents Chemother (2001) 0.99

Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase. Bioorg Med Chem (1998) 0.99

Isoprenylation of proteins in the protozoan Giardia lamblia. Mol Biochem Parasitol (1995) 0.92

Characterisation of protein isoprenylation in procyclic form Trypanosoma brucei. Mol Biochem Parasitol (1996) 0.89

Risedronate in the treatment of Murine Chagas' disease. Parasitol Res (2005) 0.89

Entamoeba histolytica: isoprenylation of p21ras and p21rap in vitro. Exp Parasitol (1996) 0.87

Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone. J Bone Miner Metab (2010) 0.83

Identification and characterisation of Toxoplasma gondii protein farnesyltransferase. Int J Parasitol (2001) 0.82

Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res Treat (1996) 0.81